European Commission approves Janssen ’s Symtuza for HIV-1 treatment

The European Commission (EC) has approved Janssen-Cilag International ’s Symtuza for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Source: Pharmaceutical Technology - September 26, 2017 Category: Pharmaceuticals Source Type: news